Gyroscope Therapeutics
Developing one-time gene therapies for retinal diseases.
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (100 %) | 27777667 % | (7 %) | (76 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3067 %) | (37317900 %) | (1333 %) | (1796 %) | (15549 %) | (24380 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3079 %) | (53529822 %) | (119 %) | (1145 %) | (16841 %) | (16965 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 18557722 % | - | - | 6196 % | - | - |
Source: Company filings or news article
Related Content
Gyroscope Therapeutics is a pioneering biotechnology company focused on developing innovative gene therapies and surgical delivery devices to treat eye diseases, particularly those leading to blindness. The company operates in the ophthalmology market, targeting conditions such as age-related macular degeneration (AMD), a leading cause of irreversible blindness in the elderly. Gyroscope collaborates with academic institutions, pharmaceutical, and biotech companies to advance clinical research and bring cutting-edge treatments to market. The business model revolves around the discovery, development, and commercialization of one-time gene therapies, which offer a potentially curative approach to eye diseases. Revenue is generated through partnerships, licensing agreements, and the eventual sale of approved therapies. Gyroscope's commitment to preserving sight and combating blindness positions it as a key player in the ophthalmology sector.
Keywords: gene therapy, ophthalmology, blindness, AMD, eye diseases, surgical devices, clinical research, biotech, partnerships, innovation.